#VisualAbstract: Treatment with adjuvant mFOLFIRINOX as compared with gemcitabine improves survival outcomes in resected pancreatic cancer
1. Median disease-free survival is longer in patients receiving mFOLFIRINOX as compared to those receiving gemcitabine. 2. Median overall survival ...